## Capricor's Deramiocel Shows Cardiovascular Promise in Pivotal DMD Trial, Fueling Market Confidence
Capricor Therapeutics Inc. (CAPR) delivered encouraging news to investors on Wednesday with the announcement of positive results from its Phase 3 HOPE-3 trial for Deramiocel, a candidate therapy addressing Duchenne muscular dystrophy. The market responded immediately, with the stock climbing over 14% during pre-market trading, reflecting investor enthusiasm for the clinical milestone.
The trial's success centers on Deramiocel's dual benefit profile. Over the 12-month study period, the therapy
Capricor Therapeutics Inc. (CAPR) delivered encouraging news to investors on Wednesday with the announcement of positive results from its Phase 3 HOPE-3 trial for Deramiocel, a candidate therapy addressing Duchenne muscular dystrophy. The market responded immediately, with the stock climbing over 14% during pre-market trading, reflecting investor enthusiasm for the clinical milestone.
The trial's success centers on Deramiocel's dual benefit profile. Over the 12-month study period, the therapy